EVIDENCE OF A DYNAMIC ROLE OF THE TARGET-CELL MEMBRANE DURING THE EARLY STAGES OF THE NATURAL-KILLER CELL LETHAL HIT

被引:0
作者
DEEM, RL
TARGAN, SR
机构
[1] UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV BASIC MED SCI, LOS ANGELES, CA 90024 USA
[2] WADSWORTH VET ADM MED CTR, CTR GERIATR RES & EDUC, LOS ANGELES, CA 90024 USA
[3] UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90024 USA
关键词
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The role of membrane movement during the stages of human NK [natural killer] cytolysis was examined by using the bifunctional protein cross-linking reagent, glutaraldehyde. The binding stage was inhibited when K562 [human leukemia] target cells or NK cells were pretreated with glutaraldehyde. When added post-binding, after initiation of Ca pulse, glutaraldehyde did not dissociate conjugates, but inhibited NK cytolysis. In contrast to the early stages of NK cytolysis, glutaraldehyde enhanced lysis during the terminal stage, killer cell independent lysis (KCIL). Lysis of the preprogrammed target cells, however, was enhanced only when glutaraldehyde was added immediately after dispersion of the conjugates, before target cell lysis. The mechanism of enhancement of lysis during the terminal stages of cytolysis was further explored in assays for NK cell-derived cytolytic factor (NKCF). L929 [mouse neoplastic fibroblast] target cells prebound with NKCF were lysed more readily in the presence of glutaraldehyde, but as in KCIL, Maximum enhancement of lysis occurred when glutaraldehyde was added immediately after NKCF was bound to the target cell. The target cell membrane may play a dynamic role during the terminal stages of the NK lethal hit.
引用
收藏
页码:72 / 77
页数:6
相关论文
共 16 条
[1]  
BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P9
[2]  
BUBBERS JE, 1975, J IMMUNOL, V114, P1126
[3]   STABILIZATION AND FUNCTIONAL-STUDIES OF HIGH-MOLECULAR-WEIGHT MURINE LYMPHOTOXINS [J].
DEVLIN, JJ ;
YAMAMOTO, RS ;
GRANGER, GA .
CELLULAR IMMUNOLOGY, 1981, 61 (01) :22-31
[4]  
ESSER AF, 1978, J IMMUNOL, V120, P1773
[5]  
FARRAM E, 1983, J IMMUNOL, V130, P1252
[6]  
GIAVEDONI EB, 1978, J IMMUNOL, V120, P2003
[7]  
GIAVEDONI EB, 1979, J IMMUNOL, V122, P1643
[8]  
HISERODT JC, 1983, J IMMUNOL, V131, P2705
[9]  
HISERODT JC, 1982, J IMMUNOL, V129, P2266
[10]  
HISERODT JC, 1982, J IMMUNOL, V129, P1782